Definium Therapeutics (DFTX) Amortizatization of Intangibles (2025 - 2026)
Definium Therapeutics (DFTX) posted quarterly Amortizatization of Intangibles of -$591000.0 for Q1 2026, down 29.04% quarter-over-quarter from -$458000.0 in Q4 2025.
Powered by 
Analysis
Definium Therapeutics (DFTX) Amortizatization of Intangibles (2025 - 2026) Analysis & Trends
Definium Therapeutics (DFTX) has reported Amortizatization of Intangibles for 2 consecutive years, with -$591000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Amortizatization of Intangibles changed N/A year-over-year to -$591000.0; the TTM figure through Mar 2026 stood at $1.2 million (changed N/A YoY), while the FY2025 annual figure was $1.8 million, changed N/A from the prior year.
- Amortizatization of Intangibles declined to -$591000.0 in Q1 2026 per DFTX's latest filing, from -$458000.0 in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $2.4 million in Q2 2025 and bottomed at -$591000.0 in Q1 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 4.33 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 678,000.00 |
| 10 | Definium Therapeutics | 4.23 Bn | 4.23 Bn | - | 1.36 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.36 Mn |
| Mar 31, 2026 | -591,000.00 |
| Dec 31, 2025 | -458,000.00 |
| Sep 30, 2025 | -143,000.00 |
| Jun 30, 2025 | 2.42 Mn |